A Single Institution’s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma

BACKGROUND: Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards to hemorrhage and thromboembolism. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Tina, Lacy, Jill, Baehring, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161684/
https://www.ncbi.nlm.nih.gov/pubmed/21892317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161684/
https://www.ncbi.nlm.nih.gov/pubmed/21892317

Ejemplares similares